Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data by unknown
ORIGINAL RESEARCH
Estimating Long-Term Survival of Adults
with Philadelphia Chromosome-Negative Relapsed/
Refractory B-Precursor Acute Lymphoblastic
Leukemia Treated with Blinatumomab Using
Historical Data
Arie Barlev . Vincent W. Lin . Aaron Katz . Kuolung Hu .
Ze Cong . Beth Barber
Received: June 27, 2016 / Published online: November 21, 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: Blinatumomab is a bispecific T
cell-engaging antibody construct indicated for
adult patients with relapsed/refractory (R/R)
Ph(-) B-precursor acute lymphoblastic
leukemia (ALL), an aggressive disease with
poor prognosis. A phase 2 single-arm clinical
study showed that 43% of patients achieved CR/
CRh within two cycles and approximately 20%
of patients receiving blinatumomab were still
alive after 2 years.
Methods: The objective of the current analysis
was to estimate long-term survival of patients
receiving blinatumomab beyond the observed
time period in the clinical study using a large
historical observational dataset. Conditional
survival probabilities of blinatumomab-treated
patients beyond month 60 were assumed to be
the same as the US general population.
Results: At month 60, the estimated
proportion of blinatumomab-treated patients
alive was more than double that of historical
patients (12.6% vs 5.4%). The mean overall
survival was 76.1 months for blinatumomab
patients and 39.8 months for historical
patients. Sensitivity analyses including
additional follow-up data from the clinical
study showed consistent results.
Conclusions: These findings suggest that
blinatumomab provides substantial overall
survival benefit to patients with (R/R) Ph(-)
B-precursor ALL compared with salvage
chemotherapy.
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INTRODUCTION
The prognosis for adult patients with
Philadelphia chromosome-negative (Ph[-])
B-precursor ALL who are refractory to treatment
or experience relapse (R/R) is poor: over 90% die
from the disease and their survival time is short
(median OS is 3–5 months) [1–4]. These patients
tend to be particularly young, with amedian age
of 34–39 years, and die, on average, 30 years
prematurely [5–7]. Ingeneral, response to salvage
treatment followed by hematopoietic stem cell
transplant (HSCT) offers the only potential for
cure and long-term survival [1, 4]. Until recently,
salvage treatment for adult patients with R/R
Ph(-) B-precursor ALL was limited to highly
toxic multi-agent chemotherapy regimens. Most
patients who receive these regimens endure
repeated and prolonged hospitalizations due to
the severity of the disease and the aggressiveness
of the treatment itself [8–11].
Blinatumomab is a novel bispecific T cell
engager (BiTE) antibody construct that
simultaneously binds CD3-positive cytotoxic T
cells and CD19-positive B cells. Blinatumomab
was approved for adults with R/R Ph(-) B-cell
precursor ALL by the FDA in December 2014
and subsequently by the European Medicines
Agency (EMA) in November 2015 [12, 13].
Regulatory approval of blinatumomab in the
US was based on results from a single-arm phase
2 study in 189 adults with R/R Ph(-)
B-precursor ALL [14]. Historical observational
data from 1139 patients with R/R Ph(-)
B-precursor ALL who received standard of care
therapy in Europe and the US provided context
for the interpretation of the single-arm clinical
study [15]. The single-arm clinical study and the
historical observational data have been
compared for rates of complete remission
(42.9% vs 24%) and overall survival (OS) at 1
(32.0% vs 15.5%) and 3 years (13.8% vs 6.2%)
[14, 15]. To date, the blinatumomab clinical
study includes 3 years of survival follow-up
data, after which time 13.8% of patients
remained alive [Amgen data on file]. In
comparison, 6.4% patients in the historical
data were alive at 3 years. The historical
observational dataset included up to 21 years
of follow up, after which time between 2% and
3% of patients remained alive. Given the very
small percentage of patients in the historical
observational dataset who lived for at least
21 years, the proportion of patients receiving
blinatumomab who were still alive after 3 years
is of particular interest.
To estimate the effect of a treatment on
long-term survival, the mean OS is a preferred
endpoint to median OS because it captures the
entire survival curve over the lifetime of a
population [16]. The objective of this analysis
was to estimate the long-term survival of
patients with R/R Ph(-) B-cell precursor ALL
receiving blinatumomab, leveraging the long





This phase 2, open-label, single-arm study was
conducted at sites across Europe and the US and
enrolled patients over the period 2010–2014
(ClinicalTrials.gov NCT01466179) [14]. Eligible
patients (N = 189) included men and women
C18 years of age with Ph(-) B-cell precursor
ALL, with one of the following characteristics:
• relapsed/refractory disease with first remission
duration B12 months in first salvage;
• relapsed/refractory disease after first salvage;
or
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• relapsed/refractory disease within 12 months
of allogeneic HSCT.
Patients with these characteristics are
considered particularly difficult to treat.
Overall survival was collected as a secondary
endpoint.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed consent was obtained from all
patients for being included in the study.
Historical Observational Dataset
A retrospective analysis was performed by
combining previously collected data from
adult R/R ALL patients in national study
groups and large treatment centers in Europe
and the US. (clinicaltrials.gov NCT02003612).
Patients were initially selected from study
group/site databases if they had a diagnosis of
R/R Ph(-) B-precursor ALL between 1990 and
2013, were aged C15 years at the time of initial
ALL diagnosis of ALL, and had no previous
treatment with blinatumomab. Patients were
further selected from the historical dataset
based on key eligibility criteria from the
blinatumomab clinical study, including age
C18 years at relapse, ALL that relapsed within
12 months from initial diagnosis, or relapsed
after alloHSCT, or refractory to initial or
subsequent treatments, or in second or later
relapse. Patients with a first remission duration
of [12 months in first salvage were excluded,
unless they had a second relapse or a relapse
within 12 months of receiving alloHSCT.
In total 1139 patients met these criteria, of
whom survival data was available from 1112
patients [15]. Two-thirds of patients (67%) were
diagnosed after the year 2000.
To calculate overall survival estimates, six
strata were created based on known prognostic
factors in R/R ALL (age, prior HSCT, and line of
salvage). Combined survival outcomes were
obtained by weighting the stratum-specific
survival estimates according to the proportion
of patients in the blinatumomab trial in each
stratum [15].
Estimation of Long-Term Overall Survival
of Patients Receiving Blinatumomab
Estimation of long-term survival was comprised
of three phases. In the first phase, survival from
months 0–25 was estimated using observed
Kaplan–Meier survival data from the primary
analysis of the blinatumomab clinical trial [14,
Amgen data on file]. In the second phase,
survival from months 26–60 was estimated
using the historical observational dataset.
Specifically, from months 26–60, we assumed
that there was no additional treatment effect
from blinatumomab—i.e., the survivors in the
blinatumomab clinical trial at months 26–60
had the same monthly conditional survival
probabilities as those in the historical
observational dataset who received salvage
chemotherapy [17, 18]. In the third phase,
since patients who survive for more than
5 years are considered to be cured of the
disease, survival from month 60 onwards was
estimated by applying the age-specific annual
conditional probability of survival from the life
tables of the US population.
Calculation of Mean OS
The mean OS for patients receiving
blinatumomab was estimated by calculating
the area under the curve (AUC) for all three
phases combined. The same AUC calculation
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was also applied to calculate the mean OS for
patients in the historical observational dataset.
Validation of Estimates Using 3 Years
of Observed Data From The Clinical Study
Additional OS data from the blinatumomab
clinical trial after 36 months of follow-up was
used to validate the long-term OS estimation
[Amgen data on file]. The three-phase method
described above was replicated using the
blinatumomab clinical trial data to estimate
survival from months 0–36, extrapolating
survival from months 37–60 using the
historical observational dataset, and
extrapolating from month 60 onwards using
conditional survival probabilities from the
general US population.
RESULTS
Details of the patient populations from the
clinical and historical studies have been
described previously, and rates of CR and OS
were compared between the blinatumomab
patients and the historical patients using
appropriate adjusted analyses [14, 15].
Observed OS Data
In both the blinatumomab clinical trial and the
historical observational dataset, the observed
OS probability decreased quickly in the first
10 months and plateaued afterwards (Fig. 1).
Comparing the observed blinatumomab
clinical trial survival curve to the historical
observational dataset survival curve, there is a
clear separation between the curves from
month zero to month 25 (Fig. 1). At month
25, the survival probability among patients
from the blinatumomab clinical trial was
18.7%, more than double the survival
probability among patients from the historical
observational dataset (8.0%) based on the
Kaplan–Meier estimate.
OS Extrapolation up to 60 Months
Based on extrapolation from the historical
observational data, the OS probability at
month 60 was 12.6% among patients from the
blinatumomab clinical study and 5.4% in the
historical observational dataset (Fig. 1).
Mean OS
The mean OS was calculated from the AUC of
all three phases of the long-term survival
estimation. The mean OS for patients in the
blinatumomab clinical study was 76.1 months
compared with 39.8 months for patients from
the historical observational dataset (Table 1).
Validation of Estimation
The long-term OS estimation based on
36 months of OS data from the blinatumomab
clinical trial was consistent with the estimation
based on 25 months of trial data plus
extrapolation with survival probabilities from
Fig. 1 5-year survival curves for patients receiving
blinatumomab and historical dataset
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the historical observational dataset (Fig. 2).
Using 36 months of survival data from the
blinatumomab clinical trial, the survival
probability at month 60 was 12.0% and the
mean OS was 74.2 months.
DISCUSSION
This study estimated long-term survival for R/R
Ph(-) ALL patients receiving blinatumomab,
using both the blinatumomab clinical trial
results and long-term natural history data.
Assuming no additional effects of
blinatumomab beyond two years, the
percentage of long-term survivors treated with
blinatumomab is estimated to be more than
double that of patients treated with salvage
chemotherapy (12.6% vs 5.4% after 5 years).
The estimation technique was validated using
an additional year of observed clinical trial data.
Similarly, the mean OS—a measure of overall
survival over the lifetime of the population—
was also approximately doubled among
blinatumomab-treated patients in comparison
to patients in the historical observational
dataset (76.1 vs 39.8 months).
The historical data set was pooled from
European national study groups and large
individual sites from Europe and the United
States. Given rarity of R/R Ph(-) B–precursor
ALL, the historical dataset represents the largest
study of its kind in adults with this disease
[13, 15], spanning over 20 years (1990–2013),
During this time, no new effective treatments
have emerged [3]. The increased use of
paediatric-inspired protocols and
improvements in supportive care and
transplant realisation may have improved
survival over time in some groups of adult R/R
ALL patients [19]. Two-thirds of patients in the
historical dataset were diagnosed after the year
2000, the survival times were similar between
the whole dataset and those patients diagnosed
from 2000 onwards [15]. The historical data
therefore appears to provide a valid reference
for survival data extrapolation and comparison
between novel agents and salvage
chemotherapy.
It is worth noting that the assumed
difference in survival between blinatumomab
and salvage chemotherapy after the observed
data time period in this study might be an
underestimation. After the observed OS data, we
assumed that the patients treated with
blinatumomab had the same conditional
survival probability as patients who received
salvage chemotherapy. In fact, patients
receiving blinatumomab can achieve a deep
response, which is known to correlate with
better long-term survival outcomes [20]. Among
81 patients with R/R Ph(-) B-precursor ALL who
achieved complete remission (CR/CRh*), 82%
Table 1 Mean overall survival estimation
Mean OSa (months)
Blinatumomab 76.06
Historical observational dataset 39.84
Difference 36.22
a Calculated by area under the curve (AUC) method
Fig. 2 Validation based on 36 months of observed data
from the blinatumomab clinical trial
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also achieved minimal residual disease
(MRD)-negativity within two cycles of
blinatumomab [14]. In an earlier clinical study
of 36 patients with Ph(-) B-cell precursor R/R
ALL, 28% of those treated with blinatumomab
survived for at least 30 months, all of whom
achieved an MRD-negative response [21]. These
findings suggest that patients treated with
blinatumomab might have higher conditional
survival probability than patients receiving
salvage chemotherapy. More patients in the
blinatumomab clinical study proceed to receive
transplants, possibly due to favourable CR rate,
or higher rate of MRD negativity [14], which is
highly correlated to positive HSCT outcome and
better overall survival, compared to those who
do not achieve MRD [22, 23].
With 12.6% of R/R ALL patients treated with
blinatumomab expected to be alive after 5 years
other treatment strategies are still required.
Treatment with blinatumomab before relapse
has been shown to produce high response rates
and survival outcomes: 78% of patients with
MRD-positive disease achieved a complete MRD
response after 1 cycle of blinatumomab, and
RFS was 58% after 18 months [24]. In a smaller
study in an MRD-positive population, after a
median of 33 months follow up, 61% of
blinatumomab-treated patients remained
relapse-free [25]. These data raise the
possibility that earlier intervention with
blinatumomab may allow long-term
remissions and reduce the need for salvage
therapy.
The blinatumomab clinical trial enrolled R/R
Ph(-) B-precursor ALL patients who were
selected for negative prognostic factors, which
represents the majority of patients but
nonetheless a subset of the total R/R Ph(-)
B-precursor ALL population. Caution needs to
be taken when extrapolating the results from
this study to the broader patient group.
Limitations of this study are inherent in the
use of historical data to compare and
extrapolate survival outcomes with data from
a clinical study. These include the assumption
of no additional effects of blinatumomab
beyond two years, potential changes in
treatment practices over time in the clinical vs
historical populations and differences in
transplant realisation rates. Nonetheless, the
superior survival outcomes with blinatumomab
treatment over standard of care have recently
been confirmed in a phase 3 study [26].
CONCLUSION
Compared to salvage chemotherapy, based on
this analysis, blinatumomab provides
substantial overall survival benefit to patients
with R/R Ph(-) B-precursor ALL.
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